For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

Last update: Feb 4, 2025

Consider BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) as an affordable growth stock, identified by our stock screening tool. NASDAQ:BMRN is showcasing impressive growth figures and is well-positioned in terms of profitability, solvency, and liquidity. Moreover, it seems to be priced reasonably. Let's dive deeper into the analysis.

Analyzing Growth Metrics

Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:BMRN boasts a 7 out of 10:

BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 127.27%, which is quite impressive.
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 19.14% in the last year.
BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.16% yearly.
Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 48.32% on average per year.
The Revenue is expected to grow by 9.76% on average over the next years. This is quite good.
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

A Closer Look at Valuation for NASDAQ:BMRN

ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NASDAQ:BMRN has earned a 7 for valuation:

94.51% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.51% of the companies listed in the same industry.
BMRN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 92.49.
95.40% of the companies in the same industry are more expensive than BMRN, based on the Enterprise Value to EBITDA ratio.
BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 94.69% of the companies in the same industry.
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
BMRN's earnings are expected to grow with 62.38% in the coming years. This may justify a more expensive valuation.

Unpacking NASDAQ:BMRN's Health Rating

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:BMRN has earned a 7 out of 10:

BMRN has an Altman-Z score of 5.91. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.91, BMRN belongs to the top of the industry, outperforming 82.48% of the companies in the same industry.
The Debt to FCF ratio of BMRN is 1.98, which is an excellent value as it means it would take BMRN, only 1.98 years of fcf income to pay off all of its debts.
BMRN's Debt to FCF ratio of 1.98 is amongst the best of the industry. BMRN outperforms 95.22% of its industry peers.
BMRN has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
A Current Ratio of 4.27 indicates that BMRN has no problem at all paying its short term obligations.
A Quick Ratio of 2.62 indicates that BMRN has no problem at all paying its short term obligations.

A Closer Look at Profitability for NASDAQ:BMRN

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:BMRN has achieved a 7:

BMRN has a Return On Assets of 4.70%. This is amongst the best in the industry. BMRN outperforms 94.87% of its industry peers.
BMRN's Return On Equity of 5.95% is amongst the best of the industry. BMRN outperforms 94.69% of its industry peers.
BMRN's Return On Invested Capital of 5.27% is amongst the best of the industry. BMRN outperforms 94.87% of its industry peers.
The Profit Margin of BMRN (11.71%) is better than 95.58% of its industry peers.
BMRN has a Operating Margin of 14.88%. This is amongst the best in the industry. BMRN outperforms 95.93% of its industry peers.
With an excellent Gross Margin value of 78.95%, BMRN belongs to the best of the industry, outperforming 86.55% of the companies in the same industry.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

Our latest full fundamental report of BMRN contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.